A polyetherimide composition, comprising: repeating units derived from one or more phenolic monomers comprising resorcinol, hydroquinone, methyl hydroquinone, t-butyl hydroquinone, di-t-butyl hydroquinones, biphenol, tetramethyl bisphenol-A, spiro biindane bisphenol, bis-(hydroxy aryl)-N-aryl isoindolinones or any combination thereof, wherein each of the one or more phenolic monomers does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay, and one or more residual phenolic monomers present at more than zero but less than or equal to 1,000 ppm, wherein the residual phenolic monomer does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay, wherein the composition further comprises one or more additives, each of the one or more additives does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay and the one or more additive comprises a phosphite which comprises a diphenyl alkyl phosphite, phenyl dialkyl phosphite, trialkyl phosphite, dialkyl phosphite, triphenyl phosphite, diphenyl pentaerythritol diphosphite, or any combination thereof; and has a molecular weight greater than 200 Daltons, and when the phosphite is subjected to conditions effective to provide one or more phosphite hydrolysis product, each of the one or more phosphite hydrolysis products does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay. repeating units derived from one or more phenolic monomers comprising resorcinol, hydroquinone, methyl hydroquinone, t-butyl hydroquinone, di-t-butyl hydroquinones, biphenol, tetramethyl bisphenol-A, spiro biindane bisphenol, bis-(hydroxy aryl)-N-aryl isoindolinones or any combination thereof, wherein each of the one or more phenolic monomers does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay, and one or more residual phenolic monomers present at more than zero but less than or equal to 1,000 ppm, wherein the residual phenolic monomer does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay, wherein the composition further comprises one or more additives, each of the one or more additives does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay and the one or more additive comprises a phosphite which comprises a diphenyl alkyl phosphite, phenyl dialkyl phosphite, trialkyl phosphite, dialkyl phosphite, triphenyl phosphite, diphenyl pentaerythritol diphosphite, or any combination thereof; and has a molecular weight greater than 200 Daltons, and when the phosphite is subjected to conditions effective to provide one or more phosphite hydrolysis product, each of the one or more phosphite hydrolysis products does not exhibit a half maximal inhibitory concentration (IC 50 ) less than 0.00025M for alpha or beta estradiol receptors determined using in vitro competition binding assay. <EOS>